List of Excipients in Branded Drug NAPHAZOLINE HCI AND PHENIRAMINE MALEATE

Generic Drugs Containing NAPHAZOLINE HCI AND PHENIRAMINE MALEATE

Company	Ingredient	NDC	Excipient
Altaire Pharmaceuticals Inc	naphazoline hydrochloride , pheniramine maleate	59390-177	BENZALKONIUM CHLORIDE
Altaire Pharmaceuticals Inc	naphazoline hydrochloride , pheniramine maleate	59390-177	BORIC ACID
Altaire Pharmaceuticals Inc	naphazoline hydrochloride , pheniramine maleate	59390-177	EDETATE DISODIUM
Altaire Pharmaceuticals Inc	naphazoline hydrochloride , pheniramine maleate	59390-177	HYPROMELLOSE
Altaire Pharmaceuticals Inc	naphazoline hydrochloride , pheniramine maleate	59390-177	SODIUM BORATE
Altaire Pharmaceuticals Inc	naphazoline hydrochloride , pheniramine maleate	59390-177	SODIUM CHLORIDE
Altaire Pharmaceuticals Inc	naphazoline hydrochloride , pheniramine maleate	59390-177	WATER

What are the Most Frequently-Used Excipients in NAPHAZOLINE HCI AND PHENIRAMINE MALEATE?

# Of NDCs	Excipient
1	BENZALKONIUM CHLORIDE
1	BORIC ACID
1	EDETATE DISODIUM
1	HYPROMELLOSE
1	SODIUM BORATE
1	SODIUM CHLORIDE
1	WATER

Naphazoline HCl and Pheniramine Maleate Excipient Strategy and Commercial Opportunities

Last updated: August 13, 2026

Naphazoline hydrochloride 0.025% and pheniramine maleate 0.3% is an established ophthalmic combination for temporary relief of ocular redness and itching associated with allergies. Its commercial value is no longer driven by active-ingredient exclusivity. The strongest opportunities are preservative-free delivery, improved tolerability, differentiated packaging, private-label supply, and compliant OTC reformulation.

The reference product, commonly associated with Naphcon-A, uses a preserved aqueous ophthalmic solution. The active ingredients are mature, low-cost, and widely understood. Competitors therefore need to differentiate through excipient selection, container-closure systems, dosing convenience, sterility assurance, and retail positioning rather than through new chemical entity protection.

What is the formulation profile of naphazoline HCl and pheniramine maleate ophthalmic products?

The combination contains an alpha-adrenergic vasoconstrictor and an H1 antihistamine.

Attribute	Naphazoline hydrochloride	Pheniramine maleate
Typical ophthalmic strength	0.025%	0.3%
Pharmacologic role	Reduces ocular redness through vasoconstriction	Reduces itching and allergic symptoms
Product category	Ophthalmic redness reliever	Ophthalmic antihistamine
Typical dosage form	Sterile aqueous solution	Sterile aqueous solution
Primary formulation risks	Overuse-related rebound redness, pH and tonicity sensitivity	Solubility, irritation, preservative compatibility
Regulatory pathway	OTC ophthalmic drug framework or approved legacy product	OTC ophthalmic drug framework or approved legacy product

The reference formulation uses water as the vehicle and commonly includes boric acid, borax, sodium chloride, edetate disodium, and benzalkonium chloride. Label-specific inactive ingredients must be verified against the current product record before use in a regulatory submission or competitive formulation program. The DailyMed label identifies the active ingredients and inactive-ingredient framework for Naphcon-A-type products. [1]

What excipients are used in naphazoline and pheniramine eye drops?

The main excipient functions are preservation, buffering, tonicity adjustment, chelation, pH control, and container compatibility.

Excipient class	Common candidate	Commercial function	Key development issue
Vehicle	Purified water	Dissolves both active ingredients	Must support sterility and chemical stability
Preservative	Benzalkonium chloride	Controls microbial growth in multidose packaging	Ocular-surface tolerability and adsorption to packaging
Buffer	Boric acid and borax	Controls pH and supports comfort	Buffer capacity must not compromise active stability
Tonicity agent	Sodium chloride	Adjusts osmolality toward tears	Excess tonicity can increase stinging
Chelator	Edetate disodium	Binds trace metals and improves preservative performance	Must be balanced against formulation compatibility
pH adjuster	Hydrochloric acid or sodium hydroxide	Final pH adjustment	Excess adjustment can increase ionic load
Alternative preservative	Polyquaternium-1, stabilized oxychloro complex, or related system	Enables differentiated preserved products	Requires preservative efficacy and ocular-tolerability data
Surfactant or wetting aid	Product-specific low-level surfactant	Improves wetting and dose delivery	May increase irritation or extractables risk

A conventional preserved solution is the lowest-cost platform. It is suitable for mass retail, pharmacy, and private-label products where price and shelf stability are more important than premium ocular-surface claims.

A preservative-free product requires a different commercial architecture. The formulation may remain an aqueous solution, but the container must prevent microbial ingress or provide single-use dosing. Unit-dose vials, blow-fill-seal packaging, or a validated multidose preservative-free pump can support a premium product.

Which excipient strategy is strongest for commercial launch?

The strongest strategy depends on the target segment.

Mass-market preserved solution

A conventional formulation using benzalkonium chloride, borate buffering, sodium chloride, edetate disodium, and purified water offers:

• Low ingredient cost
• Familiar regulatory precedent
• Compatibility with standard dropper bottles
• Broad contract-manufacturing availability
• Competitive pricing for store brands

This platform is appropriate for a direct generic or private-label product. Its weaknesses are limited differentiation and concern about repeated exposure to benzalkonium chloride, particularly among frequent users and contact-lens wearers.

Preservative-reduced or BAK-free product

A BAK-free formulation can target consumers who avoid benzalkonium chloride or who seek a product positioned for more frequent use. The key development variables are:

• Alternative antimicrobial system
• Container microbial protection
• Extractables and leachables
• Drop-size consistency
• In-use stability
• Preservative efficacy, where a preservative remains present
• Ocular-surface tolerability

A BAK-free claim can support higher pricing, but it does not by itself create patent protection. The commercial moat would reside in the formulation, package, device, clinical tolerability data, and trademark.

Preservative-free unit-dose product

Unit-dose delivery eliminates the need for a conventional preservative and reduces contamination risk after opening. It can support:

• Hospital and clinic distribution
• Allergy-season travel products
• Contact-lens-adjacent retail positioning, subject to labeling restrictions
• Premium pharmacy and e-commerce channels
• Consumer segments with preservative sensitivity

The disadvantages are higher packaging cost, greater filling complexity, more warehouse volume, and increased waste per dose.

Multidose preservative-free pump

A multidose pump can combine preservative-free positioning with improved convenience. It is potentially the most defensible platform because the commercial value may sit in the container-closure and metering system rather than in the drug composition.

The principal barriers are device qualification, sterility maintenance after repeated use, pump priming, dose uniformity, compatibility with the solution, and regulatory documentation for the integrated drug-device product.

What formulation patents could protect naphazoline and pheniramine products?

Active-ingredient patents do not provide a meaningful barrier for this combination. Naphazoline and pheniramine are established compounds, and the basic ophthalmic combination has been marketed for decades.

Potentially protectable subject matter includes:

1. Preservative-free aqueous compositions.
2. Specific alternative preservative systems.
3. Multidose container-closure assemblies.
4. Blow-fill-seal unit-dose packages.
5. Metered-dose pumps that reduce contamination.
6. Narrow pH and osmolality ranges linked to improved tolerability.
7. Formulations with reduced benzalkonium chloride exposure.
8. Long-term chemical-stability systems.
9. Manufacturing processes that improve sterility or reduce degradation.
10. Combination products with specified contact-lens or ocular-surface use conditions, where legally supportable.

A formulation patent is stronger when it claims a technically defined composition tied to measurable performance. A generic claim that merely substitutes one common buffer or preservative is vulnerable to obviousness challenges.

The most commercially relevant IP strategy is likely a package of composition, container, and manufacturing claims. The composition alone may be easy to design around. A validated delivery system with a specific microbial-barrier architecture can create a more durable barrier, particularly if it improves shelf life or permits preservative-free multidose use.

What is the FDA regulatory status of naphazoline HCl and pheniramine maleate?

Naphazoline and pheniramine fall within the FDA’s OTC ophthalmic drug framework. The relevant regulation is 21 C.F.R. Part 349, which addresses ophthalmic drug products for OTC human use. The monograph framework identifies conditions for active ingredients, labeling, dosage, and use. [2]

The standard commercial strengths of 0.025% naphazoline hydrochloride and 0.3% pheniramine maleate are associated with established allergy eye-drop products and are not new clinical concepts.

A sponsor pursuing a new product must address:

• Active-ingredient identity and assay
• Sterility
• Microbial limits and preservative effectiveness
• pH and osmolality
• Particulate matter
• Container-closure integrity
• Extractables and leachables
• Stability under labeled storage conditions
• Drop-size and delivered-dose consistency
• Compatibility with the manufacturing process
• Labeling compliance
• Drug Facts presentation
• Manufacturing under current good manufacturing practice requirements

A reformulation that falls within the applicable OTC monograph conditions may have a simpler regulatory path than a novel prescription ophthalmic product. A product with a new active strength, nonmonograph indication, unusual dosage form, or unsupported performance claim may require an FDA application or a different regulatory analysis.

What is the Orange Book status of naphazoline and pheniramine products?

The commercial market is primarily an OTC market, and Orange Book-listed patent exclusivity is not the main barrier to entry for a conventional monograph-compliant product. The FDA Orange Book focuses on approved drug applications, therapeutic equivalence, patents, and exclusivity associated with listed applications. [3]

For a standard naphazoline and pheniramine OTC product:

• There is no meaningful remaining composition-of-matter exclusivity.
• A conventional generic or store-brand product is unlikely to face an innovative-drug patent barrier comparable to newer prescription products.
• Formulation and device patents may affect a differentiated product.
• A sponsor must separately assess patents covering the reference product, package, device, trademarks, and manufacturing process.
• Patent absence does not eliminate regulatory, quality, supply-chain, or trade-dress risks.

The relevant distinction is between regulatory market access and proprietary commercial positioning. The actives are accessible, but a premium preservative-free product can still create practical barriers through packaging know-how and channel relationships.

When does naphazoline and pheniramine lose exclusivity?

The combination has already passed the period in which active-ingredient exclusivity would control market entry. No conventional new-drug exclusivity should be expected for the basic combination.

The practical exclusivity timeline is:

Exclusivity category	Current commercial relevance
New chemical entity exclusivity	Expired or inapplicable
Composition-of-matter patent	No meaningful barrier for the established actives
Basic combination patent	Expected to be expired or commercially irrelevant
Method-of-use patent	Limited value for standard allergy and redness indications
Formulation patent	Potentially relevant for a new differentiated product
Device patent	Potentially relevant for preservative-free multidose delivery
Trademark and trade dress	Relevant to consumer recognition and shelf placement
Regulatory exclusivity	Limited for a mature OTC combination

There is no expected patent cliff comparable to a blockbuster prescription drug. The market is already open to competition, subject to FDA requirements and product-specific intellectual property.

Which companies are challenging the reference product?

Competition is fragmented across branded OTC manufacturers, generic drug companies, private-label suppliers, and ophthalmic contract manufacturers. The most important competitive groups include:

• Alcon, associated with Naphcon-A and other eye-care products.
• Major consumer-health companies with allergy and redness-relief portfolios.
• Generic manufacturers supplying ophthalmic solutions.
• Retailers and pharmacy chains using private-label ophthalmic products.
• Specialty ophthalmic manufacturers offering preservative-free or device-based delivery.

The competitive threat is not limited to products containing both actives. Products containing ketotifen fumarate, olopatadine hydrochloride, or other antihistamines compete for the same allergic-eye consumer. Artificial tears and redness-relief products also compete for the same retail shelf and digital search traffic.

How does this combination compare with competing allergy eye drops?

Product category	Primary benefit	Preservative-free opportunity	Competitive position
Naphazoline plus pheniramine	Redness and itching relief	Strong	Mature, low-cost, retail-oriented
Ketotifen ophthalmic	Allergy itching relief	Moderate to strong	Strong direct allergy competitor
Olopatadine ophthalmic	Allergy symptom control	Strong	Premium branded and generic competition
Artificial tears	Lubrication and irritation relief	Very strong	High-volume substitute for mild symptoms
Naphazoline-only products	Redness relief	Moderate	Lower clinical scope for allergic itching

The combination retains a commercial niche because it addresses both redness and itching. Its weakness is the increasing consumer and professional preference for products that minimize exposure to ocular-surface preservatives and avoid repeated vasoconstrictor use.

What generic entry risks exist for naphazoline and pheniramine?

Generic entry risk is high for a standard preserved solution. A competitor can likely use a familiar aqueous platform with low technical complexity. The main barriers are:

• Sterile ophthalmic manufacturing capacity
• FDA-compliant quality systems
• Reliable supply of active ingredients and packaging
• Stability data
• Retail distribution
• Brand recognition
• Seasonal demand forecasting

A preservative-free product has greater entry friction. The formulation may be simple, but the package and manufacturing process are more difficult to qualify. This creates an opportunity for an established ophthalmic manufacturer to launch a premium alternative before low-cost competitors replicate the product.

The highest generic risk applies to:

• Standard dropper-bottle solutions
• Conventional excipient systems
• Broad allergy and redness claims
• Products sold primarily on price

The lower generic risk applies to:

• Proprietary multidose preservative-free systems
• Integrated device products
• Unit-dose products with efficient packaging
• Products with validated tolerability advantages
• Products supported by strong retail or pharmacy contracts

What manufacturing and IP barriers affect commercial launch?

Manufacturing barriers are more important than active-ingredient patent barriers.

A sponsor needs a sterile ophthalmic facility or a qualified contract manufacturer capable of:

• Aseptic filling or validated terminal sterilization, where appropriate
• Low-bioburden water systems
• Container-closure integrity testing
• Automated inspection for particles and fill volume
• Preservative assay and uniformity testing
• Stability testing in the final package
• High-volume seasonal production

The package can determine the product’s defensibility. A standard multidose bottle is easy to source and difficult to protect. A custom preservative-free pump, one-way valve, or contamination-resistant closure can support patent filings and manufacturing know-how.

Geographic coverage should be assessed separately. US OTC rules, European Union medicinal-product requirements, and other national frameworks may differ in permitted active ingredients, preservative limits, labeling, and claims. A formulation designed for the US monograph may require reformulation or a separate regulatory dossier in other jurisdictions.

What licensing deals and settlement agreements affect the market?

The mature combination has limited obvious licensing value at the active-ingredient level. The most commercially relevant licensing opportunities concern:

• Preservative-free container technologies
• Ophthalmic multidose pumps
• Blow-fill-seal manufacturing capacity
• Alternative preservative systems
• Retail private-label rights
• Regional distribution
• Co-development of allergy eye-care brands

A settlement agreement would be more likely to concern a later-developed formulation or device patent than the basic naphazoline and pheniramine combination. No Paragraph IV event is expected to control the basic OTC market in the same manner as a prescription NDA product. Paragraph IV litigation becomes relevant only if a competitor files an ANDA against a listed approved application with relevant patents. [3]

What commercial opportunities are strongest?

The most attractive opportunities are differentiated products rather than another conventional preserved solution.

Preservative-free premium product

Position the product around preservative avoidance, portability, and repeated seasonal use. The premium can support higher gross margins if packaging costs remain controlled.

Retail private label

Retailers can use the established active combination for store-brand allergy eye drops. A common formulation can be supplied in multiple labels, reducing development cost per brand.

BAK-free multidose bottle

This platform offers a compromise between consumer convenience and improved preservative positioning. It requires strong in-use stability and microbial-control data.

Unit-dose institutional product

Hospitals, clinics, and specialty practices may value single-use packaging. The opportunity is smaller than mass retail but can command better pricing.

Seasonal and e-commerce bundles

The product can be combined with oral antihistamines, nasal allergy products, or artificial tears. Demand is seasonal, so inventory planning and rapid replenishment are commercial priorities.

How strong is the patent estate for this drug combination?

The patent estate is weak for the basic active combination and potentially moderate for a differentiated delivery system.

Asset type	Estimated strategic strength
Active ingredients	Low
Basic aqueous solution	Low
Conventional borate buffer system	Low
BAK-free composition	Moderate if technically narrow
Preservative-free composition	Moderate
Multidose preservative-free device	Moderate to strong
Manufacturing process	Moderate
Brand and trade dress	Commercially relevant but not drug patent protection
Clinical tolerability evidence	Useful commercially, limited as standalone IP

A sponsor should avoid relying on a single broad formulation patent. The better approach is layered protection covering composition ranges, preservative system, package architecture, manufacturing process, and measurable performance outcomes.

Key Takeaways

• Naphazoline HCl 0.025% plus pheniramine maleate 0.3% is a mature OTC ophthalmic combination.
• The standard preserved formulation is inexpensive and exposed to generic and private-label competition.
• Benzalkonium chloride, borate buffer, sodium chloride, edetate disodium, and purified water are common excipient components in reference-style products.
• The strongest commercial opportunity is a preservative-free or BAK-free product with differentiated packaging.
• Device and container-closure technology may provide stronger protection than the formulation alone.
• No meaningful active-ingredient exclusivity or conventional patent cliff drives the market.
• Paragraph IV litigation is not expected to be the principal entry mechanism for a standard OTC monograph product.
• Licensing opportunities are concentrated in ophthalmic delivery systems, contract manufacturing, and private-label distribution.
• Competitive products containing ketotifen, olopatadine, artificial tears, and naphazoline alone limit pricing power.
• Manufacturing quality, sterility, packaging, and retail access are the primary launch barriers.

FAQs

Can naphazoline and pheniramine eye drops be reformulated without benzalkonium chloride?

Yes. A sponsor can pursue a preservative-free unit-dose product, a multidose preservative-free device, or an alternative preservative system. Each approach requires appropriate sterility, in-use stability, package-compatibility, and microbial-control data.

Is a preservative-free naphazoline and pheniramine product automatically patentable?

No. Preservative-free status alone is unlikely to support a strong patent. Patentability is more credible when the formulation includes a defined composition, a specific container-closure system, or a demonstrated technical result that is not predictable from prior art.

Does pheniramine maleate create special excipient compatibility issues?

Pheniramine maleate is water-soluble, but its compatibility with pH, ionic strength, preservatives, packaging materials, and sterilization conditions must be evaluated in the finished product. The combined formulation must be assessed for assay, degradation, clarity, particulates, and ocular tolerability.

Could a new delivery device obtain separate regulatory protection?

Yes. A multidose preservative-free pump or contamination-resistant package may create a drug-device product with device-specific regulatory and intellectual-property considerations. The device does not eliminate the need to establish drug-product quality and sterility.

Is the combination attractive for a pharmaceutical licensing deal?

It is more attractive as a platform for differentiated ophthalmic delivery than as a standalone active-ingredient license. The strongest deal structures would involve a proprietary preservative-free system, regional commercialization rights, private-label supply, or access to sterile ophthalmic manufacturing capacity.

References

1. DailyMed. (n.d.). Naphcon-A: Naphazoline hydrochloride and pheniramine maleate ophthalmic solution, USP. U.S. National Library of Medicine.
2. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 349: Ophthalmic drug products for over-the-counter human use. U.S. Government Publishing Office.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.